 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5390 News |  |
| «12...58596061626364656667686970» |
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P1/2 trial, Metastases: Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer (clinicaltrials.gov) - May 13, 2014
P1/2, N=46, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - May 5, 2014
P2, N=400, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer (clinicaltrials.gov) - May 4, 2014
P2, N=210, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2015 --> Sep 2015
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Combination therapy, Metastases: A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer (clinicaltrials.gov) - May 4, 2014
P2, N=210, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2015 --> Sep 2015 Trial completion date: Oct 2015 --> Sep 2015
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Combination therapy, Metastases: PERTAIN: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (clinicaltrials.gov) - May 4, 2014
P2, N=250, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Oct 2015 --> Sep 2015 Trial completion date: Jun 2016 --> May 2016
- |||||||||| New P3 trial: KRISTINE: A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (clinicaltrials.gov) - May 4, 2014
P3, N=432, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer (clinicaltrials.gov) - May 4, 2014
P2, N=210, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2016 --> May 2016 Active, not recruiting --> Recruiting
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Combination therapy, Metastases: PERUSE: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (clinicaltrials.gov) - May 4, 2014
P3, N=1500, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting Initiation date: Jun 2012 --> Jun 2013
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Metastases: Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=20, Recruiting, Sponsor: Rambam Health Care Campus
Initiation date: Jun 2012 --> Jun 2013 Initiation date: Apr 2014 --> May 2014
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Metastases: Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=20, Recruiting, Sponsor: Rambam Health Care Campus
Initiation date: Apr 2014 --> May 2014 Not yet recruiting --> Recruiting
- || New P3 trial: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) (clinicaltrials.gov) - Apr 21, 2014
P3, N=950, Not yet recruiting, Sponsor: German Breast Group
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P1/2 trial: TRAP: Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma (clinicaltrials.gov) - Apr 21, 2014
P1/2, N=40, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: TRAP: Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma (clinicaltrials.gov) - Apr 21, 2014
P1/2, N=40, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Trial initiation date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 15, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
Not yet recruiting --> Recruiting Initiation date: Mar 2014 --> Apr 2014
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Metastases: HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy (clinicaltrials.gov) - Apr 7, 2014
P=N/A, N=478, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Mar 2014 --> Apr 2014 Initiation date: Mar 2013 --> Jun 2013
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (clinicaltrials.gov) - Apr 7, 2014
P2, N=220, Recruiting, Sponsor: West German Study Group
Initiation date: Mar 2013 --> Jun 2013 Not yet recruiting --> Recruiting
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Metastases: HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy (clinicaltrials.gov) - Apr 7, 2014
P=N/A, N=478, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Combination therapy, Metastases: PERUSE: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (clinicaltrials.gov) - Apr 6, 2014
P3, N=1500, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting N=1220 --> 1500
- |||| Enrollment open, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 6, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
N=1220 --> 1500 Not yet recruiting --> Recruiting
- ganetespib (ADX-1612) / Aldeyra, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (clinicaltrials.gov) - Apr 6, 2014
P1, N=18, Recruiting, Sponsor: New York University School of Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: PERUSE: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (clinicaltrials.gov) - Apr 6, 2014
P3, N=1500, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Apr 3, 2014
P1, N=81, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Metastases: Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes (clinicaltrials.gov) - Mar 31, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Rambam Health Care Campus
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche
Enrollment change, Combination therapy: A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies (clinicaltrials.gov) - Mar 23, 2014
P2, N=720, Enrolling by invitation, Sponsor: Genentech
Not yet recruiting --> Recruiting N=150 --> 720
- ||||| New P2a trial, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 17, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer (clinicaltrials.gov) - Mar 13, 2014
P2, N=88, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=150 --> 720 Initiation date: Sep 2013 --> Jan 2014
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer (clinicaltrials.gov) - Mar 13, 2014
P2, N=88, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Sep 2013 --> Jan 2014 Not yet recruiting --> Recruiting
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial initiation date, IO biomarker, Metastases: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Mar 11, 2014
P1/2, N=30, Recruiting, Sponsor: University of Washington
Not yet recruiting --> Recruiting Initiation date: Nov 2013 --> Feb 2014
- AST-301 / University of Washington, Aston Sci., EpiThany
Enrollment open, IO biomarker, Metastases: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Mar 11, 2014
P1/2, N=30, Recruiting, Sponsor: University of Washington
Initiation date: Nov 2013 --> Feb 2014 Not yet recruiting --> Recruiting
- Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: TEAL: Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel (clinicaltrials.gov) - Feb 25, 2014
P2, N=30, Recruiting, Sponsor: The Methodist Hospital System
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: APHINITY: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (clinicaltrials.gov) - Feb 23, 2014
P3, N=4807, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ganetespib (ADX-1612) / Aldeyra, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P1 trial, Combination therapy, Metastases: Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (clinicaltrials.gov) - Feb 10, 2014
P1, N=18, Recruiting, Sponsor: New York University School of Medicine
- | Perjeta (pertuzumab) / Roche
Enrollment closed: Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (clinicaltrials.gov) - Feb 9, 2014
P3, N=1200, Active, not recruiting, Sponsor: German Breast Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Metastases: A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) (clinicaltrials.gov) - Feb 5, 2014
P3, N=452, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Verzenio (abemaciclib) / Eli Lilly
New P1 trial, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Feb 4, 2014
P1, N=81, Recruiting, Sponsor: Eli Lilly and Company
- | carboplatin / Generic mfg., docetaxel / Generic mfg.
Metastases: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jan 19, 2014
P3, N=212, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy, Metastases: SAPPHIRE: A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 22, 2013
P3, N=50, Recruiting, Sponsor: Hoffmann-La Roche
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (clinicaltrials.gov) - Dec 10, 2013
P3, N=437, Recruiting, Sponsor: The Netherlands Cancer Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (clinicaltrials.gov) - Dec 8, 2013
P2, N=68, Recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||||| Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - Dec 4, 2013
P2, N=152, Completed, Sponsor: Hoffmann-La Roche
- Perjeta (pertuzumab) / Roche
Enrollment open, Adverse events: The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients (clinicaltrials.gov) - Dec 4, 2013
P=N/A, N=66, Recruiting, Sponsor: OhioHealth
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. (clinicaltrials.gov) - Dec 2, 2013
P2, N=60, Not yet recruiting, Sponsor: Katherine Tkaczuk
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial: Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (clinicaltrials.gov) - Nov 25, 2013
P3, N=437, Recruiting, Sponsor: The Netherlands Cancer Institute
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Metastases: PETRA: Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) (clinicaltrials.gov) - Nov 19, 2013
P1, N=30, Recruiting, Sponsor: Ontario Clinical Oncology Group (OCOG)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, Enrollment open: Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer (clinicaltrials.gov) - Nov 17, 2013
P2, N=165, Recruiting, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib (clinicaltrials.gov) - Nov 17, 2013
P1, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed: SOLTI-Opti-HER: Study of Neoadjuvant Myocet (clinicaltrials.gov) - Nov 11, 2013
P2, N=83, Active, not recruiting, Sponsor: SOLTI Breast Cancer Research Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy, Metastases: A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer (clinicaltrials.gov) - Oct 27, 2013
P1, N=99, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial: KAITLIN: A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer (clinicaltrials.gov) - Oct 17, 2013
P3, N=2500, Recruiting, Sponsor: Hoffmann-La Roche
- | Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, New P2 trial: Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer (clinicaltrials.gov) - Oct 8, 2013
P2, N=165, Recruiting, Sponsor: Case Comprehensive Cancer Center